Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry association warns of Cancer Drugs Fund's potential to worsen regional variations in access to cancer treatments.

You may also be interested in...



Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink

Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.

Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE

Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.

European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth

It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS071713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel